April 8, 2022
NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio
March 31, 2022
NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors
March 8, 2022
NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting
March 1, 2022
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
February 28, 2022
NGM Bio to Participate in the Cowen 42nd Annual Health Care Conference
February 7, 2022
NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Displaying 11 - 20 of 22
